NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.088
+0.008 (0.74%)
Sep 2, 2026, 5:08 PM CET
NextCell Pharma AB Revenue
NextCell Pharma AB had revenue of 3.03M SEK in the quarter ending June 30, 2026, with 20.34% growth. This brings the company's revenue in the last twelve months to 10.60M, down -4.19% year-over-year. In the year 2025, NextCell Pharma AB had annual revenue of 13.96M with 26.17% growth.
Revenue (ttm)
10.60M
Revenue Growth
-4.19%
P/S Ratio
12.76
Revenue / Employee
449.10K
Employees
24
Market Cap
137.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.96M | 2.90M | 26.17% |
| Aug 31, 2025 | 11.06M | -213.75K | -1.90% |
| Dec 31, 2024 | 11.28M | 1.00 | - |
| Aug 31, 2024 | 11.28M | -2.68M | -19.18% |
| Aug 31, 2023 | 13.96M | 7.73M | 124.03% |
| Aug 31, 2022 | 6.23M | 1.78M | 39.85% |
| Aug 31, 2021 | 4.45M | 287.92K | 6.91% |
| Aug 31, 2020 | 4.17M | 2.20M | 112.11% |
| Aug 31, 2019 | 1.96M | 1.31M | 199.68% |
| Aug 31, 2018 | 655.41K | 138.21K | 26.72% |
| Aug 31, 2017 | 517.20K | - | - |
| Aug 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 136.17M |
| Xbrane Biopharma AB | 83.30M |
| Biovica International AB | 13.49M |
| Abera Bioscience AB | 9.10M |
| Elicera Therapeutics AB | 7.79M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.39M |
| Diamyd Medical AB | 432.00K |
NextCell Pharma AB News
- 6 days ago - NextCell Pharma AB Quarterly report: Q2 2026 - Filings
- 3 months ago - NextCell Pharma AB Quarterly report: Q1 2026 - Filings
- 6 months ago - NextCell Pharma AB Quarterly report: Transition period - Filings
- 9 months ago - NextCell Pharma AB Transcript: Life Science Summit 2025 - Transcripts
- 10 months ago - NextCell Pharma AB Quarterly report: Q4 2025 - Filings
- 10 months ago - NextCell Pharma AB Annual report: Q4 2025 - Filings